Background: Contrast induced nephropathy (CIN) is considered to be one of the most common major adverse effects of cardiac catheterization and is associated with short and long-term morbidity and mortality. CIN pathogenesis is still not completely understood although it is clear that the root concept is medullary hypoxia-induced renal tubular damage. Objective: The study aimed to assess the efficacy of magnesium sulphate in prevention of CIN in patients undergoing primary coronary intervention. Methodology: Our study was conducted on 100 patients who were randomly assigned to a study group IV hydration and 2 grams of intravenous magnesium sulphate group (n=50) and a control group (n=50) who were given only IV hydration Patients serum creatinine and kinetic GFR were assessed at a baseline, 2 hours and 48 hours after PPCI GFR was assessed using kinetic GFR equation, The primary end point was the occurrence of CI-AKI within 48 hrs. CI-AKI was defined as 0.5 mg/dl or more increase in serum creatinine or 25% or more increases above base line serum creatinine or drop in GFR more than 25%. Results: In the group of patients who received Magnesium sulphate before PPCI, there was a significantly lower incidence of CIN compared to the control group. A multilogistic regression model showed that magnesium sulphate had a protective role against CIN while presence of RWMA (regional wall motion abnormality) before PPCI can predict post-procedural CIN. Conclusion: Magnesium Sulphate may have a protective value and can reduce the incidence of contrast induced nephropathy after PPCI.